Aarey Drugs & Pharmaceuticals Ltd

Shares of Aarey Drugs & Pharmaceuticals Ltd plunged to their lower circuit limit on 1 Feb 2026, succumbing to intense selling pressure that saw the stock lose nearly 5% in a single session. The micro-cap pharmaceutical company’s stock performance has deteriorated sharply, reflecting mounting investor concerns and a sustained downtrend that has wiped out over 8% in the past two days.

Aarey Drugs & Pharmaceuticals Ltd witnessed a robust surge in its share price on 28 Jan 2026, hitting the upper circuit limit of 4.99% to close at ₹71.30. This significant price movement was driven by intense buying interest, resulting in a trading halt due to regulatory freeze mechanisms. The stock outperformed its sector and broader market indices, reflecting renewed investor enthusiasm despite its current Strong Sell rating.

Aarey Drugs & Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 Nov 2025. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the company’s current position as of 25 January 2026, providing investors with the latest insights into the stock’s fundamentals, valuation, financial trends, and technical outlook.

Shares of Aarey Drugs & Pharmaceuticals Ltd plunged to their lower circuit limit on 12 Jan 2026, reflecting intense selling pressure and panic among investors. The stock closed at ₹66.67, down 3.89% on the day, marking a significant underperformance relative to its sector and the broader market.

Aarey Drugs & Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 28 Nov 2025, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 02 January 2026, providing investors with the latest perspective on the company’s position.

Shares of Aarey Drugs & Pharmaceuticals Ltd plunged to their lower circuit limit on 29 Dec 2025, succumbing to intense selling pressure that saw the stock lose nearly 5% in a single session. The micro-cap pharmaceutical company’s stock closed at ₹67.65, down ₹3.12 or 4.41%, marking a continuation of a sharp downward trend amid weak investor sentiment and unfilled supply on the order books.

Aarey Drugs, a microcap player in the Pharmaceuticals & Biotechnology sector, has undergone a revision in its market evaluation reflecting recent shifts in its financial and technical outlook. This adjustment follows a detailed reassessment of the company’s quality, valuation, financial trends, and technical indicators, highlighting ongoing challenges and market dynamics affecting its performance.

Aarey Drugs & Pharmaceuticals Ltd witnessed robust buying interest on 22 Dec 2025, hitting its upper circuit limit with a maximum daily gain of 3.3%. The stock outperformed its sector and the broader Sensex, reflecting heightened investor enthusiasm despite a micro-cap market capitalisation of ₹200.66 crores.

Aarey Drugs & Pharmaceuticals Ltd witnessed a sharp decline on 15 Dec 2025, hitting its lower circuit limit as intense selling pressure gripped the stock. The pharmaceutical micro-cap recorded a maximum daily loss of 4.73%, reflecting a significant shift in market sentiment and unfilled supply overwhelming demand.

Aarey Drugs & Pharmaceuticals Ltd witnessed intense selling pressure on 10 Dec 2025, hitting its lower circuit limit and registering a maximum daily loss of 5%. The stock’s sharp decline reflects a continuation of recent negative momentum, with investors showing signs of panic selling and a significant volume of unfilled supply weighing on the price.

Aarey Drugs & Pharmaceuticals Ltd witnessed a sharp decline on 9 Dec 2025, hitting its lower circuit limit as intense selling pressure gripped the stock. The pharmaceutical micro-cap recorded a maximum daily loss of 5.0%, closing at ₹68.24, marking a significant underperformance relative to its sector and the broader market indices.

Aarey Drugs & Pharmaceuticals Ltd witnessed a sharp decline on 8 Dec 2025, hitting its lower circuit limit as intense selling pressure gripped the stock. The pharmaceutical company’s shares closed at ₹71.83, marking a maximum daily loss of 5.01%, amid signs of panic selling and unfilled supply on the bourses.

Aarey Drugs & Pharmaceuticals Ltd witnessed intense selling pressure on 4 December 2025, resulting in the stock hitting its lower circuit price limit of ₹73.49. The pharmaceutical and biotechnology company’s shares declined by 5.0% intraday, marking the maximum permissible daily loss and reflecting a sharp negative sentiment among investors.

Aarey Drugs & Pharmaceuticals has encountered significant selling pressure, with the stock registering a sharp decline of 4.99% today and exhibiting a complete absence of buyers. This marks the third consecutive day of losses, reflecting distress selling signals and a challenging trading environment for the pharmaceutical company.

Shares of Aarey Drugs & Pharmaceuticals Ltd plunged to their lower circuit limit on 3 December 2025, reflecting intense selling pressure and a sharp decline in investor confidence. The stock closed at ₹77.36, marking a maximum daily loss of 5.01%, significantly underperforming both its sector and the broader market indices.

Aarey Drugs & Pharmaceuticals Ltd has encountered significant selling pressure today, with the stock hitting a lower circuit and exhibiting a complete absence of buyers. This extreme selling activity signals distress among investors, as the pharmaceutical company’s shares continue to underperform relative to broader market indices and sector benchmarks.

Aarey Drugs & Pharmaceuticals Ltd witnessed a sharp decline on 2 Dec 2025, hitting its lower circuit limit as intense selling pressure gripped the stock. The pharmaceutical company’s shares closed at ₹81.44, marking a 5.0% drop on the day and continuing a downward trend that has seen the stock lose over 10% in the past five sessions.

Aarey Drugs & Pharmaceuticals Ltd has encountered significant selling pressure today, with the stock registering a sharp decline of 4.88% and exhibiting a complete absence of buyers. This extreme selling activity signals distress within the stock, contrasting sharply with the broader market's relatively muted movement.